Cannabinoids for control of chemotherapy induced nausea and vomiting:: quantitative systematic review

被引:364
作者
Tramèr, MR
Carroll, D
Campbell, FA
Reynolds, DJM
Moore, RA
McQuay, HJ
机构
[1] Hop Univ, Dept Anesthesiol Pharmacol Clin & Soins Intens Ch, Div Anesthesiol, CH-1211 Geneva 14, Switzerland
[2] Oxford Radcliffe Hosp, Nuffield Dept Anaesthet, Oxford OX3 7LJ, England
[3] Queens Med Ctr, Pain Management Ctr, Nottingham NG7 2UH, England
[4] Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England
来源
BMJ-BRITISH MEDICAL JOURNAL | 2001年 / 323卷 / 7303期
关键词
D O I
10.1136/bmj.323.7303.16
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To quantify the antiemetic efficacy and adverse effects of cannabis used for sickness induced by chemotherapy. Design Systematic review Data sources Systematic search (Medline, Embase, Cochrane library bibliographies), any language, to August 2000. Studies 30 randomised comparisons of cannabis with placebo or antiemetics from which dichotomous data on efficacy and harm were available (1366 patients). Oral nabilone, oral dronabind (tetrahydrocannabinol), and intramuscular levonantradol were tested. No cannabis was smoked. Follow up lasted 24 hours. Results Cannabinoids were more effective antiemetics than prochlorperazine, metoclopramide, chlorpromazine, thiethylperazine, haloperidol, domperidone, or alizapride: relative risk 1.38 (95% confidence interval 1.18 to 1.62), number needed to treat 6 for complete control of nausea; 1.28 (1.08 to 1.51), NNT 8 for complete control of vomiting: Cannabinoids were not more effective in patients receiving very low or very high emetogenic chemotherapy. In crossover trials, patients preferred cannabinoids for future chemotherapy cycles: 2.39 (2.05 to 2.78), NNT 3. Some potentially beneficial side effects occurred more often with cannabinoids: "high" 10.6 (6.86 to 16.5), NNT 3; sedation or drowsiness 1.66 (1.46 to 1.89), NNT 5; euphoria 12.5 (3.00 to 52.1), NNT 7. Harmful side effects also occurred more often with cannabinoids: dizziness 2.98 (2.31 to 3.83), NNT 3; dysphoria or depression 8.06 (3.35 to 19.2), NNT 8; hallucinations 6.10 (2.41 to 15.4), NNT 17; paranoia 8.58 (6.35 to 11.5), NNT 20; and arterial hypotension 2.23 (1.75 to 2.83),NNT 7. Patients given cannabinoids were more likely to withdraw due to side effects 4.67 (3.07 to 5.09), NNT 11. Conclusions In selected patients, the cannabinoids tested in these trials may be useful as mood enhancing adjuvants for controlling chemotherapy related sickness. Potentially serious adverse effects, even when taken short term orally or intramuscularly, are likely to limit their widespread use.
引用
收藏
页码:16 / 21
页数:10
相关论文
共 68 条
[1]   ANTI-EMETIC EFFICACY AND TOXICITY OF NABILONE, A SYNTHETIC CANNABINOID, IN LUNG-CANCER CHEMOTHERAPY [J].
AHMEDZAI, S ;
CARLYLE, DL ;
CALDER, IT ;
MORAN, F .
BRITISH JOURNAL OF CANCER, 1983, 48 (05) :657-663
[2]   Confidence intervals for the number needed to treat [J].
Altman, DG .
BRITISH MEDICAL JOURNAL, 1998, 317 (7168) :1309-1312
[3]  
[Anonymous], BMJ
[4]   DRONABINOL AS A TREATMENT FOR ANOREXIA ASSOCIATED WITH WEIGHT-LOSS IN PATIENTS WITH AIDS [J].
BEAL, JE ;
OLSON, R ;
LAUBENSTEIN, L ;
MORALES, JO ;
BELLMAN, P ;
YANGCO, B ;
LEFKOWITZ, L ;
PLASSE, TF ;
SHEPARD, KV .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1995, 10 (02) :89-97
[5]  
CHAN HSL, 1987, PEDIATRICS, V79, P946
[6]   DELTA-9-TETRAHYDROCANNABINOL AS AN ANTI-EMETIC IN CANCER-PATIENTS RECEIVING HIGH-DOSE METHOTREXATE - PROSPECTIVE, RANDOMIZED EVALUATION [J].
CHANG, AE ;
SHILING, DJ ;
STILLMAN, RC ;
GOLDBERG, NH ;
SEIPP, CA ;
BAROFSKY, I ;
SIMON, RM ;
ROSENBERG, SA .
ANNALS OF INTERNAL MEDICINE, 1979, 91 (06) :819-824
[7]  
CHANG AE, 1981, CANCER, V47, P1746
[8]  
CITRON ML, 1985, CANCER TREAT REP, V69, P109
[9]  
COLLS BM, 1980, NEW ZEAL MED J, V91, P449
[10]  
COLLS BM, 1980, LANCET, V1, P1187